Green Thumb Industries (GTII) Stock Overview
Manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
GTII Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Green Thumb Industries Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$11.38 |
| 52 Week High | CA$14.39 |
| 52 Week Low | CA$6.54 |
| Beta | 0.95 |
| 1 Month Change | 8.69% |
| 3 Month Change | 26.59% |
| 1 Year Change | 67.11% |
| 3 Year Change | 14.60% |
| 5 Year Change | -68.61% |
| Change since IPO | 27.15% |
Recent News & Updates
Narrative Update • May 28
GTII: Partial Cannabis Rescheduling Will Support Re Rating Despite Medical Efficacy Concerns
Analysts have increased their CA$ price target on Green Thumb Industries by CA$4.17 to reflect updated fair value assumptions and a higher future P/E multiple, following recent research that highlights both a raised Benchmark target and Roth's view that partial cannabis rescheduling is extremely favorable for the sector. Analyst Commentary Bullish analysts are framing the latest research on Green Thumb Industries around two key themes: updated valuation work and a more supportive regulatory backdrop for cannabis.
Narrative Update • Apr 28
GTII: Federal Rescheduling Order Will Support Key State Market Leadership
Analysts have nudged their CA$ price targets on Green Thumb Industries higher, reflecting slightly stronger revenue growth expectations, a modestly adjusted profit margin outlook, and updated P/E assumptions following what they view as an extremely favorable cannabis rescheduling order. Analyst Commentary While some research desks see the cannabis rescheduling order as extremely favorable for Green Thumb Industries, not all research is outright bullish.Recent updates
Narrative Update • May 28
GTII: Partial Cannabis Rescheduling Will Support Re Rating Despite Medical Efficacy Concerns
Analysts have increased their CA$ price target on Green Thumb Industries by CA$4.17 to reflect updated fair value assumptions and a higher future P/E multiple, following recent research that highlights both a raised Benchmark target and Roth's view that partial cannabis rescheduling is extremely favorable for the sector. Analyst Commentary Bullish analysts are framing the latest research on Green Thumb Industries around two key themes: updated valuation work and a more supportive regulatory backdrop for cannabis.Narrative Update • Apr 28
GTII: Federal Rescheduling Order Will Support Key State Market Leadership
Analysts have nudged their CA$ price targets on Green Thumb Industries higher, reflecting slightly stronger revenue growth expectations, a modestly adjusted profit margin outlook, and updated P/E assumptions following what they view as an extremely favorable cannabis rescheduling order. Analyst Commentary While some research desks see the cannabis rescheduling order as extremely favorable for Green Thumb Industries, not all research is outright bullish.Narrative Update • Apr 13
GTII: Federal Rescheduling Will Support Key State Market Leadership Despite Medical Efficacy Concerns
Analysts have raised their price target on Green Thumb Industries from CA$13.52 to CA$17.30, citing updated assumptions related to discount rates, revenue growth, profit margins, and a higher projected P/E multiple. What's in the News A large review in The Lancet reports that cannabis based medicines show little evidence of effectiveness for most mental health and substance use disorders, including anxiety, psychotic disorders, PTSD and opioid use disorder, with 54 randomized clinical trials and 2,477 participants reviewed (Reuters).Narrative Update • Mar 30
GTII: Federal Rescheduling Will Offset Medical Efficacy Concerns And Support Future Upside
Analysts have nudged their CA$ fair value estimate for Green Thumb Industries from about CA$20.39 to about CA$20.94, reflecting updated assumptions around revenue growth, profit margins and future P/E levels. What's in the News A large review published in The Lancet found little evidence that cannabis-based medicines are effective for treating most mental health and substance-use disorders, including anxiety, psychotic disorders, PTSD and opioid-use disorder.
Narrative Update • Mar 16
GTII: Rescheduling Order Will Support Higher Future Share Price
Analysts have made a modest trim to their CA$ fair value estimate for Green Thumb Industries, with the target shifting from about CA$18.13 to around CA$18.08. This adjustment reflects a balance between slightly higher revenue growth assumptions, a lower profit margin outlook, and a marginally higher future P/E multiple.Narrative Update • Mar 02
GTII: Rescheduling Order And Margin Outlook Will Support A Higher Share Price
Analysts have raised their price target on Green Thumb Industries from CA$17.00 to about CA$18.13, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E, which together modestly adjust their outlook on the shares. What's in the News President Trump signed an executive order directing Attorney General Pam Bondi to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act as quickly as possible.Narrative Update • Feb 16
GTII: Federal Rescheduling Progress Will Support Future Upside Potential
Analysts have nudged their fair value price target for Green Thumb Industries to CA$20.39, reflecting updated assumptions around revenue growth, profit margins, and a modestly lower future P/E multiple. What's in the News President Trump has instructed Attorney General Pam Bondi to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act by the end of January.Analysis Article • Feb 12
Green Thumb Industries Inc.'s (CSE:GTII) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors
Green Thumb Industries Inc. ( CSE:GTII ) shares have had a horrible month, losing 26% after a relatively good period...Narrative Update • Feb 02
GTII: Rescheduling Progress And Buybacks Will Support Future Upside Potential
Analysts have nudged their price target on Green Thumb Industries slightly lower to about US$20.39 from roughly US$20.47, pointing to updated assumptions around revenue growth, profit margin and future P/E as the drivers of this fine tuning. What's in the News President Trump signed an executive order directing Attorney General Pam Bondi to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act by the end of January.Narrative Update • Jan 19
GTII: Federal Rescheduling And Labor Stability Will Support Key State Market Leadership
Analysts have modestly adjusted their price target on Green Thumb Industries to reflect slightly different assumptions for revenue growth, profit margin, and future P/E. This has resulted in a revised fair value estimate of about $13.52 per share.Analysis Article • Jan 06
Here's Why Green Thumb Industries (CSE:GTII) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Jan 05
GTII: Regulatory Tailwinds Will Support Key State Market Leadership Through 2027
Analysts have modestly raised their price target on Green Thumb Industries to C$18, citing a higher long term revenue growth outlook, slightly richer future valuation multiples, and the company’s strong competitive positions in key state markets, despite a marginally higher discount rate and some pressure on profit margins. Analyst Commentary While the latest target price increase reflects improving confidence in Green Thumb Industries long term growth profile, not all market observers share the same level of optimism.Narrative Update • Dec 14
GTII Will Benefit From Regulatory Reform And Share Repurchase Momentum
Analysts have modestly reduced their price target on Green Thumb Industries by about $0.66 to reflect a slightly higher discount rate, while still highlighting the company’s strengthening revenue growth outlook, improving profit margins, and leading market positions that may benefit from anticipated regulatory tailwinds. Analyst Commentary Bullish analysts view Green Thumb Industries as well positioned to capture upside from a shifting regulatory landscape, particularly ahead of key political milestones that could accelerate cannabis reform.Analysis Article • Dec 13
After Leaping 36% Green Thumb Industries Inc. (CSE:GTII) Shares Are Not Flying Under The Radar
The Green Thumb Industries Inc. ( CSE:GTII ) share price has done very well over the last month, posting an excellent...Analysis Article • Dec 05
Green Thumb Industries Inc. (CSE:GTII) Shares Could Be 43% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Green Thumb Industries is CA$16.91 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Nov 13
Green Thumb Industries' (CSE:GTII) Shareholders Have More To Worry About Than Only Soft Earnings
Green Thumb Industries Inc.'s ( CSE:GTII ) stock showed strength, with investors undeterred by its weak earnings...Analysis Article • Oct 28
Investors Interested In Green Thumb Industries Inc.'s (CSE:GTII) Earnings
When close to half the companies in Canada have price-to-earnings ratios (or "P/E's") below 16x, you may consider Green...Analysis Article • Jul 11
Green Thumb Industries Inc. (CSE:GTII) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
Green Thumb Industries Inc. ( CSE:GTII ) shareholders have had their patience rewarded with a 28% share price jump in...Analysis Article • Jun 26
Is Green Thumb Industries (CSE:GTII) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • May 04
After Leaping 26% Green Thumb Industries Inc. (CSE:GTII) Shares Are Not Flying Under The Radar
Those holding Green Thumb Industries Inc. ( CSE:GTII ) shares would be relieved that the share price has rebounded 26...
New Narrative • Jan 22
Collaborations With Magnolia Bakery And DoorDash Will Expand Cannabis Brand Reach
Strategic collaborations and retail expansion are driving increased market share and revenue, with potential growth as more states legalize cannabis sales.Analysis Article • Nov 10
Here's Why Green Thumb Industries (CSE:GTII) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Sep 15
Green Thumb Industries Inc.'s (CSE:GTII) P/S Is On The Mark
When close to half the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or "P/S") below...Analysis Article • May 11
Green Thumb Industries Inc. Just Recorded A 174% EPS Beat: Here's What Analysts Are Forecasting Next
Shareholders might have noticed that Green Thumb Industries Inc. ( CSE:GTII ) filed its quarterly result this time last...Analysis Article • Apr 12
Green Thumb Industries Inc. (CSE:GTII) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Green Thumb Industries Inc. ( CSE:GTII ) shareholders would be excited to see that the share price has had a great...Analysis Article • Mar 28
Green Thumb Industries Inc.'s (CSE:GTII) Intrinsic Value Is Potentially 53% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Green Thumb Industries fair value estimate is CA$30.87 Green...Analysis Article • Feb 29
Does Green Thumb Industries (CSE:GTII) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Dec 19
Subdued Growth No Barrier To Green Thumb Industries Inc.'s (CSE:GTII) Price
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Analysis Article • Aug 31
Is Green Thumb Industries (CSE:GTII) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • May 28
Green Thumb Industries (CSE:GTII) Takes On Some Risk With Its Use Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Shareholder Returns
| GTII | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0.6% | 6.1% | -2.2% |
| 1Y | 67.1% | 71.9% | 29.3% |
Return vs Industry: GTII underperformed the Canadian Pharmaceuticals industry which returned 71.9% over the past year.
Return vs Market: GTII exceeded the Canadian Market which returned 29.3% over the past year.
Price Volatility
| GTII volatility | |
|---|---|
| GTII Average Weekly Movement | 10.7% |
| Pharmaceuticals Industry Average Movement | 11.4% |
| Market Average Movement | 10.0% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 3.8% |
Stable Share Price: GTII has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: GTII's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 4,900 | Ben Kovler | www.gtigrows.com |
Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, tinctures, edibles, topicals, capsules, tinctures, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles, RYM, and RHYTHM brands.
Green Thumb Industries Inc. Fundamentals Summary
| GTII fundamental statistics | |
|---|---|
| Market cap | CA$2.58b |
| Earnings (TTM) | CA$169.80m |
| Revenue (TTM) | CA$1.67b |
14.7x
P/E Ratio1.5x
P/S RatioIs GTII overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTII income statement (TTM) | |
|---|---|
| Revenue | US$1.20b |
| Cost of Revenue | US$620.68m |
| Gross Profit | US$575.26m |
| Other Expenses | US$454.02m |
| Earnings | US$121.24m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.55 |
| Gross Margin | 48.10% |
| Net Profit Margin | 10.14% |
| Debt/Equity Ratio | 15.3% |
How did GTII perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/11 21:43 |
| End of Day Share Price | 2026/06/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Green Thumb Industries Inc. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Russell Stanley | Beacon Securities Limited |